Mechanism and Site of Action
The pharmacological activity of ethosuximide is due to its selective blockade of T-type calcium channels.
The primary site of action is neurons within the thalamocortical region of the brain. These structures are directly responsible for generating the specific spike-wave discharges that underlie the pathogenesis of non-convulsive epileptic seizures. By interrupting this cycle, the drug stabilizes central nervous system activity.
Clinical Significance
In modern neurological practice, ethosuximide has a clearly defined role. It is recognized as the drug of choice for treating generalized absence seizures, also known as petit mal. It is generally not effective or indicated for other forms of epilepsy.
Pharmacokinetics
The drug exhibits a predictable distribution and elimination profile:
- Absorption: Following oral administration, ethosuximide is almost completely absorbed from the gastrointestinal tract, with a bioavailability approaching 100%.
- Metabolism: Biotransformation of the active substance occurs in the liver.
- Excretion: Elimination is predominantly renal. The majority of the dose is excreted as metabolites, with only about 20% eliminated unchanged.
Adverse Effects
Therapy with succinimides can be associated with adverse reactions across various organ systems:
- Gastrointestinal tract: Nausea and vomiting are the most common complaints.
- Central nervous system: Dyskinesia, headaches, drowsiness, or other sleep disturbances may occur, along with anxiety and decreased mental alertness.
- Hematologic system: In rare cases, the drug suppresses bone marrow hematopoiesis, potentially causing leukopenia and agranulocytosis.
- Immune system: There is a risk of hypersensitivity and allergic reactions.